Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
Autor: | McDonnell SL; GrassrootsHealth, Encinitas, California, United States of America., Baggerly CA; GrassrootsHealth, Encinitas, California, United States of America., French CB; GrassrootsHealth, Encinitas, California, United States of America., Baggerly LL; GrassrootsHealth, Encinitas, California, United States of America., Garland CF; Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, United States of America., Gorham ED; Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, United States of America., Hollis BW; Medical University of South Carolina, Charleston, South Carolina, United States of America., Trump DL; Inova Schar Cancer Institute, Falls Church, Virginia, United States of America., Lappe JM; Department of Medicine, Creighton University, Omaha, Nebraska, United States of America. |
---|---|
Jazyk: | angličtina |
Zdroj: | PloS one [PLoS One] 2018 Jun 15; Vol. 13 (6), pp. e0199265. Date of Electronic Publication: 2018 Jun 15 (Print Publication: 2018). |
DOI: | 10.1371/journal.pone.0199265 |
Abstrakt: | Background: While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. Objective: To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older. Methods: Analyses used pooled data from two randomized clinical trials (N = 1129, N = 2196) and a prospective cohort (N = 1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements. Results: Within the pooled cohort (N = 5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio = 0.18, P = 0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (P = 0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (P = 0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR = 0.20, P = 0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin. Conclusions: Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective. Competing Interests: Bio-Tech Pharmacal was a commercial source of funding. It did not have any relationship with GrassrootsHealth, UC San Diego, MUSC, Inova Schar, or Creighton University with regard to employment, patents, projects in development, or products marketed. Representatives of this source did not review the manuscript or play any role in design, analysis, or writing of the manuscript and had no control over any decision to publish it. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |